Standard BioTools

Executive Summary

Standard BioTools is a life sciences tools company that develops and commercializes precision genomic and proteomic solutions for translational and clinical research. Its key technology platforms include mass cytometry (CyTOF), imaging mass cytometry (Hyperion), and high-throughput microfluidics-based genomic systems (Biomark). These products enable deep biological insights with high consistency and reproducibility, positioning the company as a key supplier for researchers in oncology, immunology, and drug development. As a private company valued at approximately $354 million, Standard BioTools competes in the growing proteomics and single-cell analysis markets. The company's potential lies in expanding its installed base, advancing applications in spatial biology, and driving adoption in pharmaceutical and academic labs. However, it faces competition from emerging technologies and must continue innovating to maintain its niche.

Upcoming Catalysts (preview)

• 2026Launch of next-generation CyTOF system with enhanced sensitivity and throughput75% success
• 2026Strategic partnership or distribution agreement for Hyperion imaging mass cytometry in Asia-Pacific60% success
• 2026Publication of key studies using Biomark platform for liquid biopsy or immune monitoring70% success